Tajikistan Medical Device Registration: Risk Management and Benefit-Risk Assessment

1. Key takeaways

The expert review framework in Tajikistan lists risk as an independent evaluation dimension, placed alongside safety. Article 18(1) of Law No. 1893 provides that the expert review of medicines, medical products and quasi-medicinal products is carried out by the State Supervisory Authority for Pharmaceutical Activities on the basis of a comprehensive evaluation of safety, quality, effectiveness, economic considerations and risk. GRZAN notes that Law No. 1893 does not prescribe the format or standard of risk management documents at the statutory level, but Article 33(1), under which the biological interaction evaluation determines the acceptability of any adverse biological effects, and Article 13(5), under which products are classified by the risk level of their use, together point to a single methodology: the argumentation of risk acceptability.

2. Legal basis

3. Expert insights

Insight 1: Placing risk alongside safety shows the review distinguishes whether a product causes harm from whether that harm is acceptable. Article 18(1) lists the two as independent dimensions, a drafting technique consistent with the acceptability wording of Article 33(1). The GRZAN interpretation is that the Tajik review framework is not zero-risk oriented but acceptability oriented. In practice, this means the risk section of the dossier must state a clear conclusion that residual risk is acceptable and explain the reasoning path, rather than evading the existence of risk.

Insight 2: The withdrawal grounds in Article 21(1) are, in substance, an ex-post test of the risk acceptability conclusion. Item 6 covers the detection of dangerous side effects not stated in the instructions for use; item 7 covers an increase in cases of serious side effects already stated; item 12 covers defects in design, operating principle or manufacture execution discovered during use that affect safety. All three point to one common scenario: the risk judgment made at registration has diverged from the risk behavior observed in actual use. GRZAN recommends using Article 21(1) as a failure list for the risk management file; when drafting the risk section, companies should verify item by item that the risk control measures are sufficient to prevent these three scenarios from occurring.

Insight 3: The classification and reclassification of Article 13(5) express the risk dimension in the intensity of market access. The provision requires classification according to the risk level of use. The consequence is that the depth of risk argumentation should match the risk class of the product. The risk section for a low-risk product may be comparatively brief, while a high-risk product requires full hazard identification, probability and severity analysis, control measures, and residual risk evaluation.

Insight 4: Article 20(5) establishes a two-way flow of risk information. The provision requires the supervisory authority to take into account vigilance and monitoring information obtained domestically and abroad when making decisions on registration, re-registration, suspension and prohibition of use. The meaning is that risk events occurring abroad flow back and affect the registration status in Tajikistan. Companies should therefore include global risk data in their risk management files, not only data local to Tajikistan.

Insight 5: The absence of a prescribed risk management standard in Law No. 1893 leaves companies room to choose their methodology. The text refers only to risk and does not name ISO 14971 or any other standard. The GRZAN approach is to compile the risk file using internationally accepted risk management standards as the methodological framework, state in the document the correspondence between the chosen standard and Tajik requirements, and cite Article 8(17), on recognition of foreign standards, together with Article 1(25), on international standards for medical products, as the basis for admissibility.

4. Practical recommendations

1. Structure the risk section around acceptability argumentation. The GRZAN recommended sequence is: hazard identification, assessment of occurrence probability, assessment of consequence severity, risk control measures, residual risk evaluation, and a benefit-risk conclusion, consistent with the acceptability wording of Article 33(1).
2. Use Article 21(1) as the failure list for the risk file. When drafting the risk section, check item by item against items 6, 7 and 12, confirm the risk control measures are sufficient to prevent these scenarios, and document the corresponding relationship in the file.
3. Match the depth of risk argumentation to the product risk class. Under Article 13(5), first confirm the safety classification of the product, then determine the depth of the risk file, avoiding both over-investment and insufficient argumentation.
4. Include global risk data in the risk file. Under Article 20(5), vigilance and monitoring information from abroad affects Tajik registration and withdrawal decisions. Include global vigilance data and corrective actions already taken in the risk file.
5. Explain the correspondence between the chosen risk management standard and Tajik requirements. Citing Article 8(17) and Article 1(25), submit a standards comparison statement as the technical argument for admitting the foreign methodology.

5. Verification checklist

• □ It has been confirmed that Article 18(1) lists risk as an independent review dimension
• □ The risk section has been written in the acceptability argumentation structure
• □ Risk control measures have been verified item by item against Article 21(1)(6), (7) and (12)
• □ The depth of the risk file has been determined according to the classification of Article 13(5)
• □ Global vigilance data and corrective actions have been included in the risk file (Article 20(5))
• □ A comparison of the risk management standard with Tajik requirements has been submitted (Article 8(17), Article 1(25))
• □ A clear conclusion that residual risk is acceptable has been stated, with the reasoning path explained

Regulatory information verified as of October 29, 2026.

In the Central Asian market, GRZAN focuses its core capabilities on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a national track and a Union track coexist; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries, undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system compliant with ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com